1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Upregulation of PD-L1 in tumor microenvironment is a resistance mechanism for oncolytic virus immunotherapy
    Meeting Abstract

    Zamarin, D.; Ricca, J.; Oseledchyk, A.; Gigoux, M.; Merghoub, T.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Dissecting the mechanisms underlying antitumor effects of live oncolytic vaccinia and heat-inactivated vaccinia
    Meeting Abstract

    Wang, W.; Dai, P.; Yang, N.; Shuman, S.; Merghoub, T.; Wolchok, J.; Deng, L.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
    Meeting Abstract

    Wei, S.; Levine, J.; Cogdill, A.; Zhao, Y.; Anang, N. A.; Andrews, M.; Sharma, P.; Wang, J.; Wargo, J.; Pe'er, D.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
    Meeting Abstract

    Hirschhorn, D.; Ricca, J.; Gasmi, B.; Mangarin, L. M.; De Henau, O.; Budhu, S.; Li, Y.; Cortez, C.; Xia, Y.; Zhong, H.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Isoform specific TGF-β inhibition in combination with radiation therapy as a novel immune therapeutic approach to cancer therapy
    Meeting Abstract

    Gupta, A.; Budhu, S.; Giese, R.; van Snick, J.; Uyttenhove, C.; Ritter, G.; Wolchok, J.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma
    Meeting Abstract

    Budhu, S.; Giese, R.; De Henau, O.; Zappasodi, R.; Campesato, L. F.; Gupta, A.; Barker, C.; Freimark, B.; Wolchok, J. D.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Phase 1/1b, first-in-human study of the PI3K-gamma inhibitor IPI-549 as monotherapy and combined with nivolumab in patients with advanced solid tumors
    Meeting Abstract

    Ribas, A.; Hong, D.; Tolcher, A.; Sullivan, R.; Shapiro, G.; Chmielowski, B.; Brail, L.; Lee, L.; Mahabhashyam, S.; Ullmann, C. D.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Investigating the kynurenine pathway as a central effector mechanism of tumor immune-suppression and its potential as therapeutic target
    Meeting Abstract

    Campesato, L. F.; Budhu, S.; Zhang, X. M.; Manfredi, M. G.; McGovern, K.; Wolchok, J. D.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Heat-inactivated modified vaccinia virus Ankara (MVA) as vaccine adjuvant
    Meeting Abstract

    Yang, N.; Shuman, S.; Merghoub, T.; Wolchok, J.; Deng, L.
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save
  • Pooled 3-year overall survival data from phase II and phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma
    Meeting Abstract

    Postow, M.; Larkin, J.; Wolchok, J.; Chiarion-Sileni, V.; Hodi, F. S.; Rutkowsk, P.; Grob, J. J.; Grossmann, K.; Schadendorf, D.; Chesney, J.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save